• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In

YouScript Panel Expands to Include CYP3A4 and CYP3A5

Home / YouScript / YouScript Panel Expands to Include CYP3A4 and CYP3A5

Genelex Blog

YouScript Panel Expands to Include CYP3A4 and CYP3A5

It was previously thought that variations in CYP3A4 and CYP3A5 were either too rare or too weak to seriously affect drug metabolism, however new research and discoveries have revealed strong evidence that certain variations are powerful predictors of drug metabolism.

CYP3A4 and CYP3A5 are members of the same enzyme family as CYP2D6, CYP2C9 and CYP2C19. Because of their clinical utility, Genelex is expanding its testing repertoire and standard YouScript panel to include these two new genes.

Over 350 CYP3A4 and CYP3A5-dependent drugs are recognized in YouScript, including important cardiac and pain medication such as simvastatin, lovastatin, oxycodone and fentanyl.

Adding these genes will greatly improve YouScript’s precision and predictive ability. Prescribers should go to www.youscript.com to learn more about CYP3A4 and CYP3A5!

Genelex Resources

Affected Conditions
Affected Drugs
Info for Providers
Frequently Asked Questions
Contact Genelex
Join Our Mailing List

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.